H.C. Wainwright initiated coverage of Oruka Therapeutics with a Buy rating and $45 price target Oruka is a clinical stage biotech company developing next-generation biologics aimed at validated targets in inflammation and immunology arenas, the analyst tells investors in a research note. The firm says the company is making validated drugs better, with less frequent dosing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA: